Bamlanivimab

Despite being deauthorized by the FDA on Jan. 24, 2022, due to omicron variant inefficiency, two monoclonal antibody treatments were administered more than 158,000 times to patients with COVID-19, according to a study in JAMA Network Open.

In this episode, Joel M. Gelfand, MD, MSCE, is joined by Leonard H. Calabrese, DO, and Amesh Adalja, MD, FIDSA, as they discuss quarantine and isolation guidelines, emerging therapies to treat COVID-19, and the anticipated future of the COVID-19 pandemic.

The monoclonal antibody bamlanivimab may be effective in treating hospitalized patients with SARS-CoV-2 infection if they have no detectable levels of endogenous neutralizing antibodies prior to administration, according to researchers.

The FDA expanded the emergency use authorization of bamlanivimab plus etesevimab for the treatment of mild to moderate COVID-19 in all pediatric patients, including newborns, who are at risk for progressing to severe disease.

The monoclonal antibody cocktail of bamlanivimab plus etesevimab reduced the risk for COVID-19-related death and hospitalization among high-risk ambulatory patients compared with placebo, according to phase 3 trial results published today.

The FDA has rescinded the emergency use authorization for bamlanivimab monotherapy for the treatment of mild-to-moderate COVID-19 in adults and certain children.

Last week, AstraZeneca released data on its COVID-19 vaccine candidate and said it will submit the vaccine to the FDA for emergency use authorization in the coming weeks. It was the top story in infectious disease.

The U.S. government, in collaboration with Eli Lilly, said it has halted the distribution of the drug maker’s monoclonal antibody bamlanivimab alone to treat COVID-19 because of concerns about emerging SARS-CoV-2 variants.

The Infectious Diseases Society of America has updated its treatment guidelines for COVID-19 for several therapies, including tocilizumab, ivermectin and bamlanivimab with etesevimab.

U.S. Renal Care announced it is in the process of obtaining bamlanivimab, a monoclonal antibody therapy that has received emergency use authorization by the FDA for the treatment of mild-to-moderate COVID-19.